Nivolumab (N) plus ipilimumab (I) as first-line (1L) treatment for advanced (adv) NSCLC: 2-yr OS and long-term outcomes from CheckMate 012.

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Goldman, JW; Antonia, SJ; Gettinger, SN; Borghaei, H; Brahmer, JR; Ready, NE; Gerber, DE; Chow, LQ; Juergens, RA; Shepherd, FA; Laurie, SA; Geese, WJ; Li, A; Li, X; Hellmann, MD

Published Date

  • May 20, 2017

Published In

Volume / Issue

  • 35 / 15_suppl

Start / End Page

  • 9093 - 9093

Published By

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X

Digital Object Identifier (DOI)

  • 10.1200/jco.2017.35.15_suppl.9093